Sebacia, Inc.
7
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Multimodal Optical Imaging for Pretreatment Evaluation for Cutaneous Microparticle Delivery
Role: collaborator
Sebacia Postmarket Study of Real-World Use
Role: lead
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
Role: lead
Imaging of Pilosebaceous Units and Acne Lesions by RCM and OCT Confocal Microscopy and Optical Coherence Tomography
Role: collaborator
Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
Role: lead
A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris
Role: lead
Multiple Arm Study of Sebacia Microparticles in the Treatment of Acne Vulgaris
Role: lead
All 7 trials loaded